Therefore, activation of NK cell receptors by ligands expressed by transformed cells might be key for innate anti-tumor immunity and, as revealed here, also sets in motion adaptive immunity through production of cDC1 chemoattractants. The gene discussed is KLRD1; the disease is neoplasm.